GLOW (BPC-157 + TB-500 + GHK-Cu)

How GLOW (BPC-157 + TB-500 + GHK-Cu) works in the body

Dosing evidence

Dose at a glance

The 2.8 mg figure is mathematically coherent if the vial contains the 50/10/10 formulation. That shows the blend math works. It does not show that 2.8 mg is clinically optimal; it is a common community dose, not a clinically validated treatment dose.

Exact formula and identity

GLOW is a community or vendor formulation name, not a scientifically standardized fixed-dose drug. Before a protocol can be interpreted, the amount and exact identity of all three components need to be confirmed: GHK-Cu (mg), BPC-157 (mg), the third peptide (mg), and whether the third peptide is full-length thymosin β4 or the shorter TB-500 fragment LKKTETQ.

Community sources differ on this. PeptideFox describes its GLOW formulation as 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg full-length thymosin β4, and says it means the full 43-amino-acid thymosin β4 molecule rather than the TB-500 fragment. PeptideDosages describes a 70 mg formulation as GHK-Cu + BPC-157 + TB-500.

Community protocol examples

There is no standardized GLOW protocol. Community sources disagree:

The sources broadly agree on an approximately 50/10/10 formulation, subcutaneous use, daily or near-daily early use, GHK-Cu as the largest component, and skin and tissue-remodeling positioning. They do not agree on the exact daily dose, frequency, cycle length, maintenance schedule, washout, third-peptide nomenclature or storage period. No single schedule is a standard clinical protocol.

Frequency

Daily administration is common across community GLOW protocols, but no exact-blend human dose-frequency trial shows that daily use is better than 5 times per week, 3 times per week or any other schedule. Daily dosing is community precedent, not a clinically optimized frequency.

Timing

There is no controlled evidence that GLOW should be given in the morning, in the evening, fasted, fed, before exercise or after exercise. "Anytime" is accurate only in the sense that no timing advantage has been demonstrated.

Cycle length and breaks

Community cycles range from 4 weeks to 12 weeks, which shows the cycle is a community convention rather than a biologically established requirement. No evidence shows that a 4-week, 8-week or 12-week cycle, weekend breaks or washouts are required.

Some community protocols use 5 days on / 2 days off, but no human study has shown that this schedule is needed to prevent copper toxicity, and there is no demonstrated copper threshold that resets over a weekend.

There is also no single GLOW receptor to reset. The blend contains mechanistically different compounds (GHK-Cu, BPC-157 and thymosin β4 or TB-500), and none creates a demonstrated clinical need for a scheduled 2 to 4 week receptor reset.

Protocol logic check

Zinc and copper

The established nutritional interaction runs mainly the other way: high oral zinc intake can interfere with copper absorption in the intestine, and NIH warns that prolonged high-dose zinc can cause copper deficiency. There is no established evidence that subcutaneous GHK-Cu depletes zinc by outcompeting it in the intestine; an SC injection does not pass through intestinal absorption at all. Zinc deficiency is not an established GLOW contraindication, and routine or mandatory zinc supplementation (such as 15 to 30 mg/day) is not justified by evidence. Unnecessary zinc supplementation is not harmless, because sustained high-dose zinc can impair copper absorption and reduce copper status.

GHK-Cu does contain copper, so repeated systemic exposure reasonably raises questions about total copper exposure, copper metabolism disorders, hepatic handling and exact dose. Assessing this for a given product requires the mg of GHK-Cu per injection, estimated copper content, injection frequency, duration and other copper sources. The clinical significance of chronic systemic copper exposure from injectable GHK-Cu has not been well established.

Was the blend designed to reduce GHK-Cu injection pain?

No clinical formulation study has shown that adding BPC-157 and thymosin β4 lowers GHK-Cu injection pain, changes pH enough to improve tolerance or produces a safer formulation.

Medical literature and study context

No human trial validates the exact blend

The exact GHK-Cu + BPC-157 + thymosin β4 / TB-500 fixed-ratio injectable formulation has no matching approved label or established human efficacy program. Component evidence does not prove combined safety, compatibility, concentration or route. PeptideFox's GLOW comparison page also states that no controlled study has tested GLOW as a combined fixed-ratio intervention.

TB-500 and full-length thymosin β4 are not the same

"TB-500" is often used loosely online, but FDA uses the name for the shorter thymosin β4 fragment LKKTETQ, and states that it has not identified human exposure data for drug products containing this fragment. Full-length thymosin β4 is a different molecule with separate research, including Phase 2 studies in patients with difficult-to-heal wounds.

If a GLOW vial contains full-length thymosin β4, full-length Tβ4 literature may be relevant as component evidence. If it contains TB-500 (LKKTETQ), those full-length human trials do not apply to it. Equally, FDA's statement about no identified human exposure data for the LKKTETQ fragment does not describe full-length Tβ4. The exact sequence or form needs to be confirmed before evidence is assigned.

BPC-157 evidence is mostly preclinical

BPC-157 has a substantial animal and mechanistic literature. Recent reviews describe effects involving angiogenesis, fibroblast activity, nitric oxide signaling, tendon and muscle repair, and inflammatory pathways. Human evidence remains extremely small: a 2025 pilot IV study gave BPC-157 to two healthy adults at doses up to 20 mg IV and reported no adverse effects in those two participants. That is early human exposure data. It does not establish daily 400 mcg SC efficacy, cosmetic skin benefits, chronic safety or a role in GLOW. FDA says it has only limited safety information for proposed BPC-157 routes and highlights possible immunogenicity and characterization concerns.

Preclinical evidence supports angiogenic signaling involving VEGFR2 and nitric-oxide pathways, which gives a theoretical reason for including BPC-157 in the blend. No human GLOW trial has shown that injected BPC-157 increases dermal capillary supply, improves skin collagen through that effect, or improves GHK-Cu efficacy.

GHK-Cu evidence is real, but mostly not injectable

GHK-Cu has substantial research involving tissue remodeling, wound biology, collagen, the extracellular matrix and antioxidant signaling. Human evidence is much stronger for topical exposure than for community SC injection protocols, and even a human topical study after laser resurfacing did not show every proposed benefit. GHK-Cu biology is separate from the efficacy of injected GLOW.

Full-length thymosin β4 has human research

Unlike the TB-500 fragment, full-length thymosin β4 has human wound research, including difficult-to-heal pressure ulcers, stasis ulcers and other wound settings, with accelerated healing reported in some studies. This does not validate 400 mcg SC daily, cosmetic skin use, the GLOW ratio or 12-week GLOW cycles. GLOW does not inherit a clinical protocol from those trials.

Independent evidence

Evidence ladder

FDA regulatory picture

BPC-157. FDA says compounded BPC-157 may raise immunogenicity, peptide impurity and API-characterization concerns, and that it has limited safety information for proposed routes. In July 2026, FDA evaluated BPC-157 free base and acetate for possible inclusion on the 503A Bulks List and proposed against inclusion in its briefing materials.

TB-500. FDA defines TB-500 as the thymosin β4 fragment LKKTETQ and has not identified human exposure data for drug products containing it. Its July 2026 evaluation found information on chemical characterization, clinical safety and effectiveness insufficient, and proposed that TB-500 free base and TB-500 acetate not be placed on the 503A Bulks List. The July 23, 2026 Pharmacy Compounding Advisory Committee meeting considered both BPC-157 and TB-500. Advisory committee recommendations are nonbinding and are not drug approval; TB-500 is not FDA approved.

GHK-Cu. For injectable GHK-Cu, FDA highlights possible immunogenicity related to aggregation and peptide-related impurities, and limited human safety information. Noninjectable GHK-Cu is being evaluated separately under FDA's 503A framework.

Exact GLOW blend. Not FDA approved. There is no approved fixed-ratio GLOW product, no FDA-approved dosing and no FDA-approved cosmetic indication.

Bottom line

GLOW is a community or vendor blend, not an FDA-approved standardized drug, and the evidence for the exact blend is very limited. Component studies do not prove the combination. Whether the third component is full-length thymosin β4 or the TB-500 fragment LKKTETQ determines which evidence applies. 2.8 mg is a common community dose for the 50/10/10 formulation, not a clinically validated dose, and no FDA-approved regimen exists.

Storage

There is no FDA-approved reference GLOW formulation. Even if each of the three compounds has separate stability data, that does not show the three-peptide mixture stays chemically and physically stable together. Blend stability depends on pH, excipients, concentration, oxidation, temperature, storage time, peptide adsorption and aggregation, so formulation-specific compatibility data are required.

Some community sources, such as PeptideDosages, say reconstituted GLOW should be refrigerated and used within 4 weeks. That is community product-handling guidance. No universal validated post-reconstitution stability period, four-week or 28-day, exists for all GLOW formulations; stability information applies only to the exact formulation.

Contraindications & cautions

There is no FDA-approved GLOW label, so there are no formal GLOW-label contraindications.

FDA component warnings

All three components require regulatory caution. FDA has raised immunogenicity and characterization concerns for BPC-157 and has limited human safety information for it. FDA has identified compounded injectable GHK-Cu as raising potential immunogenicity concerns involving aggregation and peptide-related impurities, with limited human safety data. FDA's TB-500 review found no identified human exposure data for the LKKTETQ fragment.

Important cautions

• Wilson disease and copper-metabolism disorders: Wilson disease causes abnormal copper accumulation, and adding a systemic copper-containing experimental product raises clear clinical concerns. Strong biological caution.
• Active malignancy: mechanistic concerns about angiogenesis, tissue remodeling and growth signaling reasonably justify caution, but no approved label or clinical oncology dataset makes active malignancy a formal absolute contraindication. Theoretical, clinically important caution.
• Pregnancy and breastfeeding: no good exact-blend pregnancy safety data exist. Safety unknown.
• Inflammatory bowel disease: there is no controlled human GLOW program for IBD treatment, flare management or remission maintenance.

Possible side effects

There is no controlled safety dataset for the exact GLOW blend.

BPC-157 has experimental literature involving several neurotransmitter systems, but that does not make GLOW a "dopamine buffer" or make sedation or anhedonia established blend adverse effects.

Compatibility

Commonly paired with

No controlled evidence shows that any GLOW combination is synergistic.

Ingredient overlap

Adding separate BPC-157, TB-500 or thymosin β4, GHK-Cu, or KLOW on top of GLOW duplicates ingredients. The main problem is redundancy: doubling components whose combined exposure may be unclear.

Sources

1. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (BPC-157, injectable GHK-Cu, TB-500 LKKTETQ). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
2. U.S. Food and Drug Administration. July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting and briefing materials on BPC-157 and TB-500 (503A evaluation). 2026. Meeting page; BPC-157 briefing document; TB-500 briefing document
3. U.S. Food and Drug Administration. 503A bulk drug substances update (injectable versus noninjectable GHK-Cu). May 2026. https://www.fda.gov/media/94155/download
4. BPC-157 human IV pilot study (two healthy adults). 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
5. BPC-157 review (preclinical evidence, angiogenesis, VEGFR2 and nitric-oxide signaling). https://pubmed.ncbi.nlm.nih.gov/40789979/
6. Full-length thymosin β4 human wound research. https://pubmed.ncbi.nlm.nih.gov/23050815/
7. Pickart et al. Regenerative and Protective Actions of the GHK-Cu Peptide (GHK-Cu review). https://pubmed.ncbi.nlm.nih.gov/29986520/
8. Human topical GHK-Cu study after laser resurfacing. https://pubmed.ncbi.nlm.nih.gov/16847171/
9. NIH Office of Dietary Supplements. Copper: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/
10. NIH Office of Dietary Supplements. Zinc: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/
11. PeptideFox. GLOW dosage calculator (community / practitioner protocol: 50/10/10 formulation, 2.8 mg dose, phased 12-week schedule, full-length Tβ4). https://peptidefox.com/tools/glow-dosage-calculator
12. PeptideFox. GLOW vs KLOW (states the blend has not been tested as a combined fixed-ratio intervention). https://peptidefox.com/content/glow-vs-klow
13. PeptideDosages. GLOW peptide blend 70 mg vial dosage protocol (community protocol: 2.33 mg daily for 4 weeks). https://peptidedosages.com/peptide-blend-dosages/glow-peptide-blend-70-mg-vial-dosage-protocol/